CSL broke ground on an expansion of its plasma-therapy manufacturing facility in Kankakee, Illinois. The project includes a USD 1.5 billion investment to increase production of plasma-derived therapies and albumin. CSL said the expansion is expected to be operational by 2031 and will incorporate its Horizon 2 manufacturing process to increase immunoglobulin yield from the same amount of plasma. The company expects the expansion to create at least 300 new pharmaceutical roles and about 800 construction-related jobs. CSL said it has invested more than USD 3 billion in its U.S. operations since 2018.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSL Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603091101PR_NEWS_USPR_____PH05039) on March 09, 2026, and is solely responsible for the information contained therein.